<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xml:lang="en" article-type="research-article" xmlns:xlink="http://www.w3.org/1999/xlink">
<?release-delay 0|0?>
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">ETM</journal-id>
<journal-title-group>
<journal-title>Experimental and Therapeutic Medicine</journal-title>
</journal-title-group>
<issn pub-type="ppub">1792-0981</issn>
<issn pub-type="epub">1792-1015</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3892/etm.2018.6502</article-id>
<article-id pub-id-type="publisher-id">ETM-0-0-6502</article-id>
<article-categories>
<subj-group>
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Icariin prevents cytokine-induced &#x03B2;-cell death by inhibiting NF-&#x03BA;B signaling</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author"><name><surname>Zhong</surname><given-names>Shao</given-names></name>
<xref rid="af1-etm-0-0-6502" ref-type="aff">1</xref>
<xref rid="af2-etm-0-0-6502" ref-type="aff">2</xref>
<xref rid="c2-etm-0-0-6502" ref-type="corresp"/></contrib>
<contrib contrib-type="author"><name><surname>Ge</surname><given-names>Jing</given-names></name>
<xref rid="af3-etm-0-0-6502" ref-type="aff">3</xref></contrib>
<contrib contrib-type="author"><name><surname>Yu</surname><given-names>Jiang-Yi</given-names></name>
<xref rid="af3-etm-0-0-6502" ref-type="aff">3</xref>
<xref rid="c1-etm-0-0-6502" ref-type="corresp"/></contrib>
</contrib-group>
<aff id="af1-etm-0-0-6502"><label>1</label>Department of Endocrinology, Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210023, P.R. China</aff>
<aff id="af2-etm-0-0-6502"><label>2</label>Department of Endocrinology, Affiliated Kunshan Hospital of Jiangsu University, Kunshan, Jiangsu 215300, P.R. China</aff>
<aff id="af3-etm-0-0-6502"><label>3</label>Department of Endocrinology, Jiangsu Province Hospital of Traditional Chinese Medicine, Affiliated Hospital of Nanjing University of Traditional Chinese Medicine, Nanjing, Jiangsu 210029, P.R. China</aff>
<author-notes>
<corresp id="c1-etm-0-0-6502"><italic>Correspondence to</italic>: Professor Jiang-Yi Yu, Department of Endocrinology, Jiangsu Province Hospital of Traditional Chinese Medicine, Affiliated Hospital of Nanjing University of Traditional Chinese Medicine, 155 Hanzhong Road, Qinhuai, Nanjing, Jiangsu 210029, P.R. China, E-mail: <email>yujiangyi2007@163.com</email></corresp>
<corresp id="c2-etm-0-0-6502">Dr Shao Zhong, Department of Endocrinology, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing, Jiangsu 210023, P.R. China, E-mail: <email>shaozhong@189.cn</email></corresp>
</author-notes>
<pub-date pub-type="ppub">
<month>09</month>
<year>2018</year></pub-date>
<pub-date pub-type="epub">
<day>20</day>
<month>07</month>
<year>2018</year></pub-date>
<volume>16</volume>
<issue>3</issue>
<fpage>2756</fpage>
<lpage>2762</lpage>
<history>
<date date-type="received"><day>29</day><month>01</month><year>2018</year></date>
<date date-type="accepted"><day>17</day><month>05</month><year>2018</year></date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2018, Spandidos Publications</copyright-statement>
<copyright-year>2018</copyright-year>
</permissions>
<abstract>
<p>The loss of insulin secretion in type I diabetes mellitus (T1DM) is caused by autoimmune-mediated destruction of insulin-producing pancreatic &#x03B2;-cells. Inflammatory cytokines and immune cell infiltration activate oxidative and endoplasmic reticulum (ER) stress, resulting in reduced &#x03B2;-cell viability. The current pharmacological agents used to control blood glucose have a limited effective duration and are accompanied by strong side effects. Blocking the inflammatory and immune responses that cause the &#x03B2;-cell damage has been investigated as a novel therapeutic approach to control T1DM. Icariin is a flavonoid component of Chinese medicinal herbs that has anti-inflammatory effects <italic>in vitro</italic> and <italic>in vivo</italic>. The results of the present study revealed that icariin abrogates the pro-apoptotic effect of inflammatory cytokines and significantly suppresses the activation of nuclear factor (NF)-&#x03BA;B in rat pancreatic &#x03B2;-cell lines. The present study may provide a basis for the potential use of icariin as a therapeutic agent for T1DM.</p>
</abstract>
<kwd-group>
<kwd>icariin</kwd>
<kwd>cytokine</kwd>
<kwd>nuclear factor-&#x03BA;B</kwd>
<kwd>&#x03B2;-cell</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>The incidence of diabetes mellitus (DM), a complex metabolic disorder associated with defective insulin secretion and activity, has been increasing worldwide over the past 20 years (<xref rid="b1-etm-0-0-6502" ref-type="bibr">1</xref>,<xref rid="b2-etm-0-0-6502" ref-type="bibr">2</xref>). According to the World Health Organization estimation, ~7&#x0025; of the world&#x0027;s adult population is diabetic and the diabetic population is likely to increase to &#x2265;300 million by the year 2025 (<xref rid="b3-etm-0-0-6502" ref-type="bibr">3</xref>). Type 1 DM (T1DM) is an organ-specific autoimmune disease associated with failure to distinguish self- from non-self-antigens (<xref rid="b4-etm-0-0-6502" ref-type="bibr">4</xref>). It is caused by T cell-mediated destruction of insulin-producing pancreatic &#x03B2;-cells (<xref rid="b4-etm-0-0-6502" ref-type="bibr">4</xref>). The incidence of T1DM is increasing steadily by 3&#x0025; annually and has a concordance rate of 40&#x2013;60&#x0025; for monozygotic twins (<xref rid="b4-etm-0-0-6502" ref-type="bibr">4</xref>). As such, environmental and genetic factors may contribute to disease onset (<xref rid="b5-etm-0-0-6502" ref-type="bibr">5</xref>&#x2013;<xref rid="b7-etm-0-0-6502" ref-type="bibr">7</xref>). Currently, insulin therapy is the primary treatment for T1DM. However, tight glycemic control is difficult to achieve in a number of patients, leading to long-term vascular damage associated with kidney failure, heart disease, retinopathy and neuropathy (<xref rid="b8-etm-0-0-6502" ref-type="bibr">8</xref>). Recent advances in pancreatic islet transplantation and partial or whole pancreas transplantation represent alternate treatment options for T1DM (<xref rid="b9-etm-0-0-6502" ref-type="bibr">9</xref>). However, due to the limited number of organs available for transplant, this approach is not widely used (<xref rid="b9-etm-0-0-6502" ref-type="bibr">9</xref>). Since &#x03B2;-cell damage is crucial to the development of T1DM, treatments that are able to prevent &#x03B2;-cell damage may slow disease progression.</p>
<p>Pancreatic &#x03B2;-cell damage is known to be mediated by the immune response (<xref rid="b10-etm-0-0-6502" ref-type="bibr">10</xref>&#x2013;<xref rid="b12-etm-0-0-6502" ref-type="bibr">12</xref>). Previous studies have suggested that inflammatory cytokines and immune cell infiltration activate oxidative and endoplasmic reticulum (ER) stress and damage &#x03B2;-cell viability (<xref rid="b10-etm-0-0-6502" ref-type="bibr">10</xref>&#x2013;<xref rid="b16-etm-0-0-6502" ref-type="bibr">16</xref>). In the early stages of disease, the infiltration of inflammatory cells promotes the release of cytokines, including interleukin-1&#x03B2; (IL-1&#x03B2;), tumor necrosis factor-&#x03B1; (TNF-&#x03B1;) and interferon-&#x03B3; (IFN-&#x03B3;) (<xref rid="b15-etm-0-0-6502" ref-type="bibr">15</xref>&#x2013;<xref rid="b16-etm-0-0-6502" ref-type="bibr">16</xref>). IL-1&#x03B2;, alone or in combination with TNF-&#x03B1; or IFN-&#x03B3;, upregulates the expression of inducible nitric oxide synthase (iNOS) and promotes the generation of nitric oxide (NO) in pancreatic islets (<xref rid="b17-etm-0-0-6502" ref-type="bibr">17</xref>,<xref rid="b18-etm-0-0-6502" ref-type="bibr">18</xref>). Excessive NO production leads to dysfunctions of mitochondrial metabolism, protein modification and DNA cleavage, which may contribute to the impairment of insulin secretion and triggering &#x03B2;-cell death (<xref rid="b19-etm-0-0-6502" ref-type="bibr">19</xref>).</p>
<p>Considering the inflammatory nature of T1DM, it is plausible that anti-inflammatory agents may have potential as anti-DM drugs. Icariin is a naturally occurring flavonoid isolated from traditional Chinese medicinal herbs of the <italic>Epimedium</italic> genus (<xref rid="b20-etm-0-0-6502" ref-type="bibr">20</xref>). The compound has been revealed to have anti-inflammatory, antidepressant, male reproductive, antineoplastic, bone-healing and neuroprotective effects (<xref rid="b20-etm-0-0-6502" ref-type="bibr">20</xref>). Early <italic>in vivo</italic> and <italic>in vitro</italic> studies revealed that icariin acts as a natural anti-inflammatory drug via multiple mechanisms targeting pro-inflammatory cytokines (TNF-&#x03B1; and IL-6), inflammatory mediators (NO) and adhesion molecules (CD11b) (<xref rid="b21-etm-0-0-6502" ref-type="bibr">21</xref>,<xref rid="b22-etm-0-0-6502" ref-type="bibr">22</xref>). Xu <italic>et al</italic> (<xref rid="b23-etm-0-0-6502" ref-type="bibr">23</xref>) reported that icariin activates the phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) signaling pathway to ameliorate lipopolysaccharide (LPS)-induced acute inflammatory responses. The known anti-inflammatory effects of icariin suggest that it may inhibit inflammation-induced &#x03B2;-cell death. The aim of the present study was to use rat pancreatic &#x03B2;-cell lines as an <italic>in vitro</italic> model to investigate the role of icariin. The results suggest that icariin inhibits cytokine-induced NF-&#x03BA;B activation and prevents &#x03B2;-cell death.</p>
</sec>
<sec sec-type="materials|methods">
<title>Materials and methods</title>
<sec>
<title/>
<sec>
<title>Cell culture</title>
<p>Rat pancreatic &#x03B2;-cell RINm5F cells were obtained from ATCC (Manassas, VA, USA). Cells were cultured in RPMI-1640 medium (Hyclone; GE Healthcare Life Sciences, Logan, UT, USA) with 10&#x0025; (v/v) heat-inactivated fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA), 2 mM glutamine (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany), 1&#x0025; non-essential amino acids (Sigma-Aldrich; Merck KGaA), 100 U/ml streptomycin and 100 U/ml penicillin (Sigma-Aldrich; Merck KGaA) at 37&#x00B0;C in an atmosphere containing 5&#x0025; CO<sub>2</sub>. Icariin was purchased from Sigma-Aldrich (Merck KGaA). Rat IL-1&#x03B2; and IFN-&#x03B3; proteins were obtained from R&#x0026;D Systems (Minneapolis, MN, USA).</p>
</sec>
<sec>
<title>MTT assay</title>
<p>MTT (Sigma-Aldrich; Merck KGaA) was used to determine cell viability according to the manufacturer&#x0027;s protocols. Briefly, 5 ml MTT solvent (Beyotime Institute of Biotechnology, Haimen, China) was used to dissolve 25 mg MTT to form an MTT solution at 5 mg/ml. A total of 10 &#x00B5;1 MTT solution was added to each well and incubated for 4 h at 37&#x00B0;C in an incubator. Subsequently, 100 &#x00B5;l formazan solution (Beyotime Institute of Biotechnology) was added for 4 h at 37&#x00B0;C. The optical density of viable cells was measured using a microplate reader (BMG Labtech GmbH, Ortenburg, Germany) at a wavelength of 570 nm.</p>
</sec>
<sec>
<title>NO measurement</title>
<p>Biologically synthesized NO is quickly oxidized to form nitrite and nitrate in aqueous solutions (<xref rid="b19-etm-0-0-6502" ref-type="bibr">19</xref>). Therefore, detecting the nitrite concentration in cell-free culture supernatants using a colorimetric assay may be indicative of NO generation. In brief, RINm5F cells (5&#x00D7;10<sup>6</sup>) or 30 islets were treated with the 5 or 10 &#x00B5;M concentrations of icariin for 3 h, prior to being treated with IL-1&#x03B2; (1 U/ml) and IFN-&#x03B3; (100 U/ml) for 24 h. Subsequently, 100 &#x00B5;l aliquots of culture supernatant were incubated at room temperature for 5 min with 100 &#x00B5;l modified Griess reagent in a 1:1 mixture of 1&#x0025; sulfanilamide in 30&#x0025; acetic acid and 0.1&#x0025; N-(1-naphthyl) ethylenediamine dihydrochloride in 60&#x0025; acetic acid (Beyotime Institute of Biotechnology). The absorbance was measured at 540 nm. The NO concentration was calculated from the linear standard curve of serial dilutions of sodium nitrite in a working medium.</p>
</sec>
<sec>
<title>Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)</title>
<p>Total RNA was extracted from cultured cells using TRIzol reagent (Thermo Fisher Scientific, Inc.). The primer for iNOS was synthesized based on the following previously published sequences (<xref rid="b24-etm-0-0-6502" ref-type="bibr">24</xref>): Forward, 5&#x2032;-GAATCTTGGAGCGAGTTGTGG-3&#x2032; and reverse, 5&#x2032;-AGGAAGTAGGTGAGGGCTTGG-3&#x2032;. First-strand cDNA was obtained using Super M-MLV Reverse transcriptase (BioTeke Corporation, Beijing, China). Reverse transcription was performed at 42&#x00B0;C for 15 min and 72&#x00B0;C for 2 min according to the manufacturer&#x0027;s protocols. PCR was performed using SYBR-Green master mix (Beijing Solarbio Science &#x0026; Technology Co., Ltd., Beijing, China). The following thermocycling conditions were used: Predenaturation at 95&#x00B0;C for 30 sec followed by 40 cycles of amplification at 95&#x00B0;C for 5 sec and annealing and extension at 60&#x00B0;C for 30 sec. GADPH was used to normalize iNOS mRNA expression. GAPDH forward, 5&#x2032;-GATGACCTTGCCCACAGCCT-3&#x2032; and reverse, 5&#x2032;-ATCTCTGCCCCCTCTGCTGA-3&#x2032;. The 2<sup>&#x2212;&#x2206;&#x2206;Cq</sup> method was used to quantify data (<xref rid="b24-etm-0-0-6502" ref-type="bibr">24</xref>). ABI Prism 7000 software (Applied Biosystems; Thermo Fisher Scientific, Inc.) was used to analyze data.</p>
</sec>
<sec>
<title>Western blotting</title>
<p>Following treatment, proteins were extracted from RINm5F cells using a Nuclear and Cytoplasmic Protein Extraction kit (cat. no. P0027; Beyotime Institute of Biotechnology). Protein concentrations were determined using an Enhanced BCA Protein Assay kit (cat. no. P0010S; Beyotime Institute of Biotechnology). A total of 20 &#x00B5;g/lane was separated by 12&#x0025; SDS-PAGE and transferred to polyvinylidene difluoride membranes (EMD Millipore, Billerica, MA, USA). The membranes were blocked using Blocking Buffer (cat. no. P0023B; Beyotime Institute of Biotechnology) for 2 h at room temperature. Proteins were probed using specific primary antibodies at 4&#x00B0;C overnight, followed by incubation with secondary antibodies at room temperature for 1 h. Specific primary antibodies against pro-caspase-3 (ab44976; 1:500), cleaved caspase-3 (ab13847; 1:500) and cleaved poly ADP-ribose polymerase (PARP; ab32064; 1:2,000) were purchased from Abcam (Cambridge, UK). Secondary antibodies against &#x03B2;-actin (ab8227; 1:2,000) and Larmin A (ab26300; 1:1,000) used in this study were horseradish peroxidase (HRP) conjugated goat anti-rabbit IgG or anti-mouse IgG-HRP (Beyotime Institute of Biotechnology). &#x03B2;-actin and Larmin A were used as internal controls to normalize results. Signals were monitored using a chemiluminescent substrate (KPL, Inc., Gaithersburg, MD, USA). Following electrophoresis, gray values were analyzed using Quantity One v4.4.0.36 software (Bio-Rad Laboratories, Inc., Hercules, CA, USA).</p>
</sec>
<sec>
<title>Caspase-3 activity</title>
<p>The activity of caspase-3 was conducted using a commercial ELISA kit (cat. no. HC079; Shanghai Gefan Biotechnology Co., Ltd., Shanghai, China) according to the manufacturer&#x0027;s protocols. In brief, cells (1&#x00D7;10<sup>6</sup>) were resuspended in 50 &#x00B5;l lysis buffer (Shanghai Gefan Biotechnology Co., Ltd.) and incubated for 1 h in an ice bath. The supernatant was collected following centrifugation for 10 min at 800 &#x00D7; g at room temperature, following which a colorimetric reagent was added and incubated for 4 h at 37&#x00B0;C. The colorimetric product was monitored using an ELISA reader at a wavelength of 405 nm.</p>
</sec>
<sec>
<title>Apoptosis detection using flow cytometry</title>
<p>A total of 1&#x00D7;10<sup>6</sup> cells were washed with PBS and resuspended in binding buffer containing Annexin V-APC and propidium iodide, and incubated at 20&#x2013;25&#x00B0;C for 10&#x2013;20 min (Beyotime Institute of Biotechnology). The samples were analyzed using a FACScan flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA). The percentage of apoptotic cells in a 10,000-cell cohort was determined using flow cytometry.</p>
</sec>
<sec>
<title>NF-&#x03BA;B P65 activity</title>
<p>Following treatment, nuclear extracts were isolated using the Nuclear Extract kit according to the manufacturer&#x0027;s protocols (Active Motif, Carlsbad, CA, USA; cat. no. 40010). The activity of NF-&#x03BA;B p65 was assessed using an ELISA kit (cat. no. 40596; Active Motif).</p>
</sec>
<sec>
<title>Statistical analysis</title>
<p>Values are presented as the mean &#x00B1; standard deviation. Statistical comparisons between cell lines were performed using one-way analysis of variance, followed by Dunnett&#x0027;s t-test. GraphPad Prism 7.03 software (GraphPad Software Inc., La Jolla, CA, USA) was used to analyze experimental data and a P&#x003C;0.05 was considered to indicate a statistically significant difference.</p>
</sec>
</sec>
</sec>
<sec sec-type="results">
<title>Results</title>
<sec>
<title/>
<sec>
<title>Icariin prevents cytokine-induced loss of cell viability</title>
<p>To assess the therapeutic potential of icariin in rat pancreatic &#x03B2; cells, the viability of cultured RINm5F cells was initially examined. As presented in <xref rid="f1-etm-0-0-6502" ref-type="fig">Fig. 1</xref>, treatment with icariin up to 10 &#x00B5;M did not result in a significant loss of cell viability. Next, whether icariin protected RINm5F cells from cytokine toxicity was investigated. Treatment with cytokines IL-1&#x03B2; and IFN-&#x03B3; significantly reduced the cell viability to 49.9&#x00B1;5.2&#x0025; of the control value (<xref rid="f1-etm-0-0-6502" ref-type="fig">Fig. 1</xref>). Pretreatment with icariin significantly abrogated the cytotoxic effects of cytokines on RINm5F cells in a concentration-dependent manner.</p>
</sec>
<sec>
<title>Icariin prevents cytokine-induced NO production</title>
<p>NO production was significantly increased following 24 h treatment with cytokines (<xref rid="f2-etm-0-0-6502" ref-type="fig">Fig. 2A</xref>). However, the cytokine-induced NO production was effectively inhibited by treatment with 10 &#x00B5;M icariin (<xref rid="f2-etm-0-0-6502" ref-type="fig">Fig. 2A</xref>). To investigate the underlying mechanisms responsible for the effects of icariin, RT-qPCR and western blotting were performed to measure the expression of iNOS at the mRNA and protein level, respectively. Treatment with IL-1&#x03B2; and IFN-&#x03B3; significantly increased the expression of iNOS, while icariin treatment significantly ameliorated this increase at the mRNA and protein level (<xref rid="f2-etm-0-0-6502" ref-type="fig">Fig. 2</xref>).</p>
</sec>
<sec>
<title>Icariin prevents cytokine-induced apoptosis</title>
<p>Cytokines are able to promote &#x03B2;-cell death through apoptosis and necrosis (<xref rid="b25-etm-0-0-6502" ref-type="bibr">25</xref>). Caspase-3 serves a pivotal role in the apoptotic signaling pathway, and so the activation status of caspase-3 was assessed in the present study. Treatment with IL-1&#x03B2; and IFN-&#x03B3; increased the activity of caspase-3 and cell apoptosis in RINm5F cells, while icariin effectively reversed these effects (<xref rid="f3-etm-0-0-6502" ref-type="fig">Fig. 3</xref>). The activation of apoptotic signaling was also confirmed by western blotting (<xref rid="f3-etm-0-0-6502" ref-type="fig">Fig. 3B</xref>). Cleaved caspase-3 is the main marker of cell apoptosis (<xref rid="b26-etm-0-0-6502" ref-type="bibr">26</xref>), and so its expression was assessed. As presented in <xref rid="f3-etm-0-0-6502" ref-type="fig">Fig. 3B</xref>, IL-1&#x03B2; and IFN-&#x03B3; were able to activate caspase-3 and increase the cleavage of PARP in RINm5F cells, while treatment with icariin reduced cleaved caspase-3 and cleaved PARP levels in cytokine-stimulated cells.</p>
</sec>
<sec>
<title>Icariin suppresses the cytokine-induced activation of NF-&#x03BA;B</title>
<p>NF-&#x03BA;B is a key transcription factor that induces iNOS and regulates subsequent NO production (<xref rid="b27-etm-0-0-6502" ref-type="bibr">27</xref>). The results of a previous study by our group demonstrated that NF-&#x03BA;B was activated by cytokines or oxidative stress (<xref rid="b28-etm-0-0-6502" ref-type="bibr">28</xref>). Based on this, it was investigated whether icariin affects the cytokine-induced activation and translocation of NF-&#x03BA;B from the cytosol to the nucleus in RINm5F cells. NF-&#x03BA;B and the nuclear translocation of p65, a key subunit of the NF-&#x03BA;B complex, were significantly promoted by treatment with IL-1&#x03B2; and IFN-&#x03B3; compared with the control (<xref rid="f4-etm-0-0-6502" ref-type="fig">Fig. 4</xref>). In contrast, icariin pretreatment markedly suppressed the cytokine-stimulated activation and nuclear translocation of NF-&#x03BA;B. In summary, these data suggest that icariin may downregulate iNOS expression via inhibiting the cytokine-stimulated activation of NF-&#x03BA;B.</p>
</sec>
</sec>
</sec>
<sec sec-type="discussion">
<title>Discussion</title>
<p>Icariin is a biologically active flavonoid with a favorable therapeutic profile in metabolic syndrome (<xref rid="b29-etm-0-0-6502" ref-type="bibr">29</xref>,<xref rid="b30-etm-0-0-6502" ref-type="bibr">30</xref>). Notably, icariin has been reported to ameliorate streptozocin-induced rat diabetic retinopathy and nephropathy (<xref rid="b31-etm-0-0-6502" ref-type="bibr">31</xref>,<xref rid="b32-etm-0-0-6502" ref-type="bibr">32</xref>). A previous study demonstrated that icariin could serve as a peroxisome proliferator-activated receptor &#x03B1; agonist, which activates gene expression associated with lipid metabolism in the liver to contribute towards diabetes management (<xref rid="b33-etm-0-0-6502" ref-type="bibr">33</xref>). In the present study, it was revealed that icariin is able to prevent cytokine-induced &#x03B2;-cell death, which is an important cause of T1DM.</p>
<p>Inflammation is the primary cause of T1DM as well as a direct cause of a number of diabetic complications (<xref rid="b34-etm-0-0-6502" ref-type="bibr">34</xref>). An acute, intense inflammatory response triggers T1DM through lymphocyte-mediated destruction of pancreatic &#x03B2; cells. A chronic state of low-grade inflammation persists within in the body, which is periodically exacerbated by hyperglycemic fluctuations (<xref rid="b34-etm-0-0-6502" ref-type="bibr">34</xref>&#x2013;<xref rid="b35-etm-0-0-6502" ref-type="bibr">35</xref>). Increased inflammation markers (<xref rid="b35-etm-0-0-6502" ref-type="bibr">35</xref>), immune activation (<xref rid="b36-etm-0-0-6502" ref-type="bibr">36</xref>) and oxidative stress have been recorded in patients with T1DM (<xref rid="b37-etm-0-0-6502" ref-type="bibr">37</xref>,<xref rid="b38-etm-0-0-6502" ref-type="bibr">38</xref>). It has therefore been hypothesized that anti-inflammatory agents may be an effective clinical treatment for patients with T1DM. A number of <italic>in vivo</italic> and <italic>in vitro</italic> studies have confirmed the anti-inflammatory effect of icariin, including in the brain, heart, bones and airways (<xref rid="b22-etm-0-0-6502" ref-type="bibr">22</xref>,<xref rid="b23-etm-0-0-6502" ref-type="bibr">23</xref>,<xref rid="b39-etm-0-0-6502" ref-type="bibr">39</xref>&#x2013;<xref rid="b50-etm-0-0-6502" ref-type="bibr">50</xref>). The present study demonstrated that icariin prevents viability loss in rat pancreatic &#x03B2; cells, as well as suppressing cytokine-induced NO production and apoptosis activation. These results suggest that icariin may interfere with the inflammatory response and resulting pancreatic &#x03B2; cell death during T1DM.</p>
<p>Furthermore, a key factor in cytokine-induced pancreatic &#x03B2;-cell damage is NF-&#x03BA;B. <italic>In vivo</italic> studies of transgenic mice revealed that NF-&#x03BA;B inhibition is a protective mechanism against cytokine-induced apoptosis in pancreatic &#x03B2;-cells (<xref rid="b28-etm-0-0-6502" ref-type="bibr">28</xref>). In addition, the use of A20-overexpressing islets to abrogate NF-&#x03BA;B signaling during islet transplantation reduces the number of islets required to achieve euglycemia in diabetic recipients (<xref rid="b51-etm-0-0-6502" ref-type="bibr">51</xref>). Therefore, suppression of the NF-&#x03BA;B pathway may also be a novel strategy for delaying the progression of T1DM. The regulatory role of icariin on NF-&#x03BA;B has been reported, however it may vary between different cell types (<xref rid="b20-etm-0-0-6502" ref-type="bibr">20</xref>). Xu and Huang (<xref rid="b52-etm-0-0-6502" ref-type="bibr">52</xref>) demonstrated that icariin could increase the expression of endothelial NOS in human endothelial cells, which was implicated in the activation of NF-&#x03BA;B (<xref rid="b53-etm-0-0-6502" ref-type="bibr">53</xref>). In contrast, icariin was able to abrogate the effects of LPS on neuroinflammation, lung inflammation, osteoclast differentiation and bone resorption via decreasing NF-&#x03BA;B activity (<xref rid="b23-etm-0-0-6502" ref-type="bibr">23</xref>,<xref rid="b49-etm-0-0-6502" ref-type="bibr">49</xref>,<xref rid="b54-etm-0-0-6502" ref-type="bibr">54</xref>,<xref rid="b55-etm-0-0-6502" ref-type="bibr">55</xref>). It has also been reported that icariin inhibits NF-&#x03BA;B activity in a wide range of cancerous cells (<xref rid="b56-etm-0-0-6502" ref-type="bibr">56</xref>&#x2013;<xref rid="b59-etm-0-0-6502" ref-type="bibr">59</xref>). The results of the present study demonstrated that icariin suppresses the cytokine-induced activation of NF-&#x03BA;B in rat pancreatic &#x03B2; cells. It is likely that icariin exerts cell-specific regulatory effects and only suppresses high levels of NF-&#x03BA;B activity in tumor cells or cells stimulated by inflammatory cytokines.</p>
<p>The results of the present study demonstrate that icariin abrogates the pro-apoptotic effect of cytokines and significantly suppresses NF-&#x03BA;B activation in rat pancreatic &#x03B2;-cells. Despite being used extensively as a model for the human pancreas, the physiology of rat pancreatic &#x03B2; cells does not perfectly mimic that of primary cells (<xref rid="b60-etm-0-0-6502" ref-type="bibr">60</xref>). The RINm5F cells used in the present study have limitations in terms of glucose sensitivity, transport and phosphorylation (<xref rid="b60-etm-0-0-6502" ref-type="bibr">60</xref>,<xref rid="b61-etm-0-0-6502" ref-type="bibr">61</xref>). Therefore, experiments utilizing human pancreatic cells and <italic>in vivo</italic> analysis are required to confirm these findings. Nevertheless, the results of the present study suggest that icariin may have potential as a therapeutic agent against T1DM.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgements</title>
<p>Not applicable.</p>
</ack>
<sec>
<title>Funding</title>
<p>The present study was supported by the National Natural Science Foundation of China (grant no. 81573911).</p>
</sec>
<sec>
<title>Availability of data and materials</title>
<p>The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.</p>
</sec>
<sec>
<title>Authors&#x0027; contributions</title>
<p>SZ and J-YY conceived the study, acquired data, interpreted the results and drafted the manuscript. JG made substantial contributions to the experiments and data analysis.</p>
</sec>
<sec>
<title>Ethics approval and consent to participate</title>
<p>Not applicable.</p>
</sec>
<sec>
<title>Patient consent for publication</title>
<p>Not applicable.</p>
</sec>
<sec>
<title>Competing interests</title>
<p>The authors declare that they have no competing interests.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="b1-etm-0-0-6502"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Philippe</surname><given-names>J</given-names></name><name><surname>Raccah</surname><given-names>D</given-names></name></person-group><article-title>Treating type 2 diabetes: How safe are current therapeutic agents?</article-title><source>Int J Clin Pract</source><volume>63</volume><fpage>321</fpage><lpage>332</lpage><year>2009</year><pub-id pub-id-type="doi">10.1111/j.1742-1241.2008.01980.x</pub-id><pub-id pub-id-type="pmid">19196370</pub-id></element-citation></ref>
<ref id="b2-etm-0-0-6502"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akkati</surname><given-names>S</given-names></name><name><surname>Sam</surname><given-names>KG</given-names></name><name><surname>Tungha</surname><given-names>G</given-names></name></person-group><article-title>Emergence of promising therapies in diabetes mellitus</article-title><source>J Clin Pharmacol</source><volume>51</volume><fpage>796</fpage><lpage>804</lpage><year>2011</year><pub-id pub-id-type="doi">10.1177/0091270010376972</pub-id><pub-id pub-id-type="pmid">20705952</pub-id></element-citation></ref>
<ref id="b3-etm-0-0-6502"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>King</surname><given-names>H</given-names></name><name><surname>Aubert</surname><given-names>RE</given-names></name><name><surname>Herman</surname><given-names>WH</given-names></name></person-group><article-title>Global burden of diabetes, 1995&#x2013;2025: Prevalence, numerical estimates and projections</article-title><source>Diabetes Care</source><volume>21</volume><fpage>1414</fpage><lpage>1431</lpage><year>1998</year><pub-id pub-id-type="doi">10.2337/diacare.21.9.1414</pub-id><pub-id pub-id-type="pmid">9727886</pub-id></element-citation></ref>
<ref id="b4-etm-0-0-6502"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab collab-type="corp-author">American Diabetes Association</collab></person-group><article-title>Diagnosis and classification of diabetes mellitus</article-title><source>Diabetes Care</source><volume>31</volume><supplement>Suppl 1</supplement><fpage>S55</fpage><lpage>S60</lpage><year>2008</year><pub-id pub-id-type="doi">10.2337/dc08-S055</pub-id><pub-id pub-id-type="pmid">18165338</pub-id></element-citation></ref>
<ref id="b5-etm-0-0-6502"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patterson</surname><given-names>CC</given-names></name><name><surname>Gyurus</surname><given-names>E</given-names></name><name><surname>Rosenbauer</surname><given-names>J</given-names></name><name><surname>Cinek</surname><given-names>O</given-names></name><name><surname>Neu</surname><given-names>A</given-names></name><name><surname>Schober</surname><given-names>E</given-names></name><name><surname>Parslow</surname><given-names>RC</given-names></name><name><surname>Joner</surname><given-names>G</given-names></name><name><surname>Svensson</surname><given-names>J</given-names></name><name><surname>Castell</surname><given-names>C</given-names></name><etal/></person-group><article-title>Trends in childhood type 1 diabetes incidence in Europe during 1989&#x2013;2008: Evidence of non-uniformity over time in rates of increase</article-title><source>Diabetologia</source><volume>55</volume><fpage>2142</fpage><lpage>2147</lpage><year>2012</year><pub-id pub-id-type="doi">10.1007/s00125-012-2571-8</pub-id><pub-id pub-id-type="pmid">22638547</pub-id></element-citation></ref>
<ref id="b6-etm-0-0-6502"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patterson</surname><given-names>CC</given-names></name><name><surname>Dahlquist</surname><given-names>GG</given-names></name><name><surname>Gyurus</surname><given-names>E</given-names></name><name><surname>Green</surname><given-names>A</given-names></name><name><surname>Solt&#x00E9;sz</surname><given-names>G</given-names></name><collab collab-type="corp-author">EURODIAB Study Group</collab></person-group><article-title>Incidence trends for childhood type 1 diabetes in Europe during 1989&#x2013;2003 and predicted new cases 2005&#x2013;20: a multicentre prospective registration study</article-title><source>Lancet</source><volume>373</volume><fpage>2027</fpage><lpage>2033</lpage><year>2009</year><pub-id pub-id-type="doi">10.1016/S0140-6736(09)60568-7</pub-id><pub-id pub-id-type="pmid">19481249</pub-id></element-citation></ref>
<ref id="b7-etm-0-0-6502"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Redondo</surname><given-names>MJ</given-names></name><name><surname>Jeffrey</surname><given-names>J</given-names></name><name><surname>Fain</surname><given-names>PR</given-names></name><name><surname>Eisenbarth</surname><given-names>GS</given-names></name><name><surname>Orban</surname><given-names>T</given-names></name></person-group><article-title>Concordance for islet autoimmunity among monozygotic twins</article-title><source>N Engl J Med</source><volume>359</volume><fpage>2849</fpage><lpage>2850</lpage><year>2008</year><pub-id pub-id-type="doi">10.1056/NEJMc0805398</pub-id><pub-id pub-id-type="pmid">19109586</pub-id></element-citation></ref>
<ref id="b8-etm-0-0-6502"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davidson</surname><given-names>MH</given-names></name></person-group><article-title>Cardiovascular risk factors in a patient with diabetes mellitus and coronary artery disease: Therapeutic approaches to improve outcomes: Perspectives of a preventive cardiologist</article-title><source>Am J Cardiol</source><volume>110</volume><supplement>9 Suppl</supplement><fpage>43B</fpage><lpage>49B</lpage><year>2012</year><pub-id pub-id-type="doi">10.1016/j.amjcard.2012.08.033</pub-id><pub-id pub-id-type="pmid">23062566</pub-id></element-citation></ref>
<ref id="b9-etm-0-0-6502"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robertson</surname><given-names>RP</given-names></name></person-group><article-title>Islet transplantation a decade later and strategies for filling a half-full glass</article-title><source>Diabetes</source><volume>59</volume><fpage>1285</fpage><lpage>1291</lpage><year>2010</year><pub-id pub-id-type="doi">10.2337/db09-1846</pub-id><pub-id pub-id-type="pmid">20508222</pub-id></element-citation></ref>
<ref id="b10-etm-0-0-6502"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ehses</surname><given-names>JA</given-names></name><name><surname>Perren</surname><given-names>A</given-names></name><name><surname>Eppler</surname><given-names>E</given-names></name><name><surname>Ribaux</surname><given-names>P</given-names></name><name><surname>Pospisilik</surname><given-names>JA</given-names></name><name><surname>Maor-Cahn</surname><given-names>R</given-names></name><name><surname>Gueripel</surname><given-names>X</given-names></name><name><surname>Ellingsgaard</surname><given-names>H</given-names></name><name><surname>Schneider</surname><given-names>MK</given-names></name><name><surname>Biollaz</surname><given-names>G</given-names></name><etal/></person-group><article-title>Increased number of islet-associated macrophages in type 2 diabetes</article-title><source>Diabetes</source><volume>56</volume><fpage>2356</fpage><lpage>2370</lpage><year>2007</year><pub-id pub-id-type="doi">10.2337/db06-1650</pub-id><pub-id pub-id-type="pmid">17579207</pub-id></element-citation></ref>
<ref id="b11-etm-0-0-6502"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eizirik</surname><given-names>DL</given-names></name><name><surname>Sammeth</surname><given-names>M</given-names></name><name><surname>Bouckenooghe</surname><given-names>T</given-names></name><name><surname>Bottu</surname><given-names>G</given-names></name><name><surname>Sisino</surname><given-names>G</given-names></name><name><surname>Igoillo-Esteve</surname><given-names>M</given-names></name><name><surname>Ortis</surname><given-names>F</given-names></name><name><surname>Santin</surname><given-names>I</given-names></name><name><surname>Colli</surname><given-names>ML</given-names></name><name><surname>Barthson</surname><given-names>J</given-names></name><etal/></person-group><article-title>The human pancreatic islet transcriptome: expression of candidate genes for type 1 diabetes and the impact of pro-inflammatory cytokines</article-title><source>PLoS Genet</source><volume>8</volume><fpage>e1002552</fpage><year>2012</year><pub-id pub-id-type="doi">10.1371/journal.pgen.1002552</pub-id><pub-id pub-id-type="pmid">22412385</pub-id></element-citation></ref>
<ref id="b12-etm-0-0-6502"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wellen</surname><given-names>KE</given-names></name><name><surname>Hotamisligil</surname><given-names>GS</given-names></name></person-group><article-title>Inflammation, stress and diabetes</article-title><source>J Clin Invest</source><volume>115</volume><fpage>1111</fpage><lpage>1119</lpage><year>2005</year><pub-id pub-id-type="doi">10.1172/JCI200525102</pub-id><pub-id pub-id-type="pmid">15864338</pub-id></element-citation></ref>
<ref id="b13-etm-0-0-6502"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arif</surname><given-names>S</given-names></name><name><surname>Moore</surname><given-names>F</given-names></name><name><surname>Marks</surname><given-names>K</given-names></name><name><surname>Bouckenooghe</surname><given-names>T</given-names></name><name><surname>Dayan</surname><given-names>CM</given-names></name><name><surname>Planas</surname><given-names>R</given-names></name><name><surname>Vives-Pi</surname><given-names>M</given-names></name><name><surname>Powrie</surname><given-names>J</given-names></name><name><surname>Tree</surname><given-names>T</given-names></name><name><surname>Marchetti</surname><given-names>P</given-names></name><etal/></person-group><article-title>Peripheral and islet interleukin-17 pathway activation characterizes human autoimmune diabetes and promotes cytokine-mediated beta-cell death</article-title><source>Diabetes</source><volume>60</volume><fpage>2112</fpage><lpage>2119</lpage><year>2011</year><pub-id pub-id-type="doi">10.2337/db10-1643</pub-id><pub-id pub-id-type="pmid">21659501</pub-id></element-citation></ref>
<ref id="b14-etm-0-0-6502"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atkinson</surname><given-names>MA</given-names></name><name><surname>Eisenbarth</surname><given-names>GS</given-names></name><name><surname>Michels</surname><given-names>AW</given-names></name></person-group><article-title>Type 1 diabetes</article-title><source>Lancet</source><volume>383</volume><fpage>69</fpage><lpage>82</lpage><year>2014</year><pub-id pub-id-type="doi">10.1016/S0140-6736(13)60591-7</pub-id><pub-id pub-id-type="pmid">23890997</pub-id></element-citation></ref>
<ref id="b15-etm-0-0-6502"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baldwin</surname><given-names>AC</given-names></name><name><surname>Green</surname><given-names>CD</given-names></name><name><surname>Olson</surname><given-names>LK</given-names></name><name><surname>Moxley</surname><given-names>MA</given-names></name><name><surname>Corbett</surname><given-names>JA</given-names></name></person-group><article-title>A role for aberrant protein palmitoylation in FFA-induced ER stress and beta-cell death</article-title><source>Am J Physiol Endocrinol Metab</source><volume>302</volume><fpage>E1390</fpage><lpage>E1398</lpage><year>2012</year><pub-id pub-id-type="doi">10.1152/ajpendo.00519.2011</pub-id><pub-id pub-id-type="pmid">22436701</pub-id></element-citation></ref>
<ref id="b16-etm-0-0-6502"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imai</surname><given-names>Y</given-names></name><name><surname>Dobrian</surname><given-names>AD</given-names></name><name><surname>Weaver</surname><given-names>JR</given-names></name><name><surname>Butcher</surname><given-names>MJ</given-names></name><name><surname>Cole</surname><given-names>BK</given-names></name><name><surname>Galkina</surname><given-names>EV</given-names></name><name><surname>Morris</surname><given-names>MA</given-names></name><name><surname>Taylor-Fishwick</surname><given-names>DA</given-names></name><name><surname>Nadler</surname><given-names>JL</given-names></name></person-group><article-title>Interaction between cytokines and inflammatory cells in islet dysfunction, insulin resistance and vascular disease</article-title><source>Diabetes Obes Metab</source><volume>15</volume><supplement>Suppl 3</supplement><fpage>S117</fpage><lpage>S129</lpage><year>2013</year><pub-id pub-id-type="doi">10.1111/dom.12161</pub-id></element-citation></ref>
<ref id="b17-etm-0-0-6502"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cnop</surname><given-names>M</given-names></name><name><surname>Welsh</surname><given-names>N</given-names></name><name><surname>Jonas</surname><given-names>JC</given-names></name><name><surname>J&#x00F6;rns</surname><given-names>A</given-names></name><name><surname>Lenzen</surname><given-names>S</given-names></name><name><surname>Eizirik</surname><given-names>DL</given-names></name></person-group><article-title>Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities</article-title><source>Diabetes</source><volume>54</volume><supplement>Suppl 2</supplement><fpage>S97</fpage><lpage>S107</lpage><year>2005</year><pub-id pub-id-type="doi">10.2337/diabetes.54.suppl_2.S97</pub-id><pub-id pub-id-type="pmid">16306347</pub-id></element-citation></ref>
<ref id="b18-etm-0-0-6502"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eizirik</surname><given-names>DL</given-names></name><name><surname>Colli</surname><given-names>ML</given-names></name><name><surname>Ortis</surname><given-names>F</given-names></name></person-group><article-title>The role of inflammation in insulitis and beta-cell loss in type 1 diabetes</article-title><source>Nat Rev Endocrinol</source><volume>5</volume><fpage>219</fpage><lpage>226</lpage><year>2009</year><pub-id pub-id-type="doi">10.1038/nrendo.2009.21</pub-id><pub-id pub-id-type="pmid">19352320</pub-id></element-citation></ref>
<ref id="b19-etm-0-0-6502"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corbett</surname><given-names>JA</given-names></name><name><surname>McDaniel</surname><given-names>ML</given-names></name></person-group><article-title>Does nitric oxide mediate autoimmune destruction of beta-cells? Possible therapeutic interventions in IDDM</article-title><source>Diabetes</source><volume>41</volume><fpage>897</fpage><lpage>903</lpage><year>1992</year><pub-id pub-id-type="doi">10.2337/diab.41.8.897</pub-id><pub-id pub-id-type="pmid">1378415</pub-id></element-citation></ref>
<ref id="b20-etm-0-0-6502"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>JH</given-names></name><name><surname>Ning</surname><given-names>Y</given-names></name><name><surname>Shen</surname><given-names>ZY</given-names></name></person-group><article-title>Icariin and its pharmaceutical efficacy: research progress of molecular mechanism</article-title><source>Zhong Xi Yi Jie He Xue Bao</source><volume>9</volume><fpage>1179</fpage><lpage>1184</lpage><year>2011</year> <comment>(In Chinese)</comment><pub-id pub-id-type="doi">10.3736/jcim20111104</pub-id><pub-id pub-id-type="pmid">22088582</pub-id></element-citation></ref>
<ref id="b21-etm-0-0-6502"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>JF</given-names></name><name><surname>Dong</surname><given-names>JC</given-names></name><name><surname>Xu</surname><given-names>CQ</given-names></name></person-group><article-title>Effects of icariin on inflammation model stimulated by lipopolysaccharide in vitro and in vivo</article-title><source>Zhongguo Zhong Xi Yi Jie He Za Zhi</source><volume>29</volume><fpage>330</fpage><lpage>334</lpage><year>2009</year> <comment>(In Chinese)</comment><pub-id pub-id-type="pmid">19526759</pub-id></element-citation></ref>
<ref id="b22-etm-0-0-6502"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>MH</given-names></name><name><surname>Sun</surname><given-names>JS</given-names></name><name><surname>Tsai</surname><given-names>SW</given-names></name><name><surname>Sheu</surname><given-names>SY</given-names></name><name><surname>Chen</surname><given-names>MH</given-names></name></person-group><article-title>Icariin protects murine chondrocytes from lipopolysaccharide-induced inflammatory responses and extracellular matrix degradation</article-title><source>Nutr Res</source><volume>30</volume><fpage>57</fpage><lpage>65</lpage><year>2010</year><pub-id pub-id-type="doi">10.1016/j.nutres.2009.10.020</pub-id><pub-id pub-id-type="pmid">20116661</pub-id></element-citation></ref>
<ref id="b23-etm-0-0-6502"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>CQ</given-names></name><name><surname>Liu</surname><given-names>BJ</given-names></name><name><surname>Wu</surname><given-names>JF</given-names></name><name><surname>Xu</surname><given-names>YC</given-names></name><name><surname>Duan</surname><given-names>XH</given-names></name><name><surname>Cao</surname><given-names>YX</given-names></name><name><surname>Dong</surname><given-names>JC</given-names></name></person-group><article-title>Icariin attenuates LPS-induced acute inflammatory responses: involvement of PI3K/Akt and NF-kappaB signaling pathway</article-title><source>Eur J Pharmacol</source><volume>642</volume><fpage>146</fpage><lpage>153</lpage><year>2010</year><pub-id pub-id-type="doi">10.1016/j.ejphar.2010.05.012</pub-id><pub-id pub-id-type="pmid">20519138</pub-id></element-citation></ref>
<ref id="b24-etm-0-0-6502"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bae</surname><given-names>UJ</given-names></name><name><surname>Lee da</surname><given-names>Y</given-names></name><name><surname>Song</surname><given-names>MY</given-names></name><name><surname>Lee</surname><given-names>SM</given-names></name><name><surname>Park</surname><given-names>JW</given-names></name><name><surname>Ryu</surname><given-names>JH</given-names></name><name><surname>Park</surname><given-names>BH</given-names></name></person-group><article-title>A prenylated flavan from Broussonetia kazinoki prevents cytokine-induced beta-cell death through suppression of nuclear factor-kB activity</article-title><source>Biol Pharm Bull</source><volume>34</volume><fpage>1026</fpage><lpage>1031</lpage><year>2011</year><pub-id pub-id-type="doi">10.1248/bpb.34.1026</pub-id><pub-id pub-id-type="pmid">21720008</pub-id></element-citation></ref>
<ref id="b25-etm-0-0-6502"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saldeen</surname><given-names>J</given-names></name></person-group><article-title>Cytokines induce both necrosis and apoptosis via a common Bcl-2-inhibitable pathway in rat insulin-producing cells</article-title><source>Endocrinology</source><volume>141</volume><fpage>2003</fpage><lpage>2010</lpage><year>2000</year><pub-id pub-id-type="doi">10.1210/endo.141.6.7523</pub-id><pub-id pub-id-type="pmid">10830283</pub-id></element-citation></ref>
<ref id="b26-etm-0-0-6502"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tewari</surname><given-names>M</given-names></name><name><surname>Quan</surname><given-names>LT</given-names></name><name><surname>O&#x0027;Rourke</surname><given-names>K</given-names></name><name><surname>Desnoyers</surname><given-names>S</given-names></name><name><surname>Zeng</surname><given-names>Z</given-names></name><name><surname>Beidler</surname><given-names>DR</given-names></name><name><surname>Poirier</surname><given-names>GG</given-names></name><name><surname>Salvesen</surname><given-names>GS</given-names></name><name><surname>Dixit</surname><given-names>VM</given-names></name></person-group><article-title>Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly (ADP-ribose) polymerase</article-title><source>Cell</source><volume>81</volume><fpage>801</fpage><lpage>809</lpage><year>1995</year><pub-id pub-id-type="doi">10.1016/0092-8674(95)90541-3</pub-id><pub-id pub-id-type="pmid">7774019</pub-id></element-citation></ref>
<ref id="b27-etm-0-0-6502"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heimberg</surname><given-names>H</given-names></name><name><surname>Heremans</surname><given-names>Y</given-names></name><name><surname>Jobin</surname><given-names>C</given-names></name><name><surname>Leemans</surname><given-names>R</given-names></name><name><surname>Cardozo</surname><given-names>AK</given-names></name><name><surname>Darville</surname><given-names>M</given-names></name><name><surname>Eizirik</surname><given-names>DL</given-names></name></person-group><article-title>Inhibition of cytokine-induced NF-kappaB activation by adenovirus-mediated expression of a NF-kappaB super-repressor prevents beta-cell apoptosis</article-title><source>Diabetes</source><volume>50</volume><fpage>2219</fpage><lpage>2224</lpage><year>2001</year><pub-id pub-id-type="doi">10.2337/diabetes.50.10.2219</pub-id><pub-id pub-id-type="pmid">11574401</pub-id></element-citation></ref>
<ref id="b28-etm-0-0-6502"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eldor</surname><given-names>R</given-names></name><name><surname>Yeffet</surname><given-names>A</given-names></name><name><surname>Baum</surname><given-names>K</given-names></name><name><surname>Doviner</surname><given-names>V</given-names></name><name><surname>Amar</surname><given-names>D</given-names></name><name><surname>Ben-Neriah</surname><given-names>Y</given-names></name><name><surname>Christofori</surname><given-names>G</given-names></name><name><surname>Peled</surname><given-names>A</given-names></name><name><surname>Carel</surname><given-names>JC</given-names></name><name><surname>Boitard</surname><given-names>C</given-names></name><etal/></person-group><article-title>Conditional and specific NF-kappaB blockade protects pancreatic beta cells from diabetogenic agents</article-title><source>Proc Natl Acad Sci USA</source><volume>103</volume><fpage>5072</fpage><lpage>5077</lpage><year>2006</year><pub-id pub-id-type="doi">10.1073/pnas.0508166103</pub-id><pub-id pub-id-type="pmid">16551748</pub-id></element-citation></ref>
<ref id="b29-etm-0-0-6502"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gong</surname><given-names>Y</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Xie</surname><given-names>GY</given-names></name><name><surname>Liu</surname><given-names>HR</given-names></name><name><surname>Qi</surname><given-names>MY</given-names></name></person-group><article-title>Amelioration of icariin for the epididymis impairment induced by streptozocin (STZ) in rats</article-title><source>Zhongguo Ying Yong Sheng Li Xue Za Zhi</source><volume>29</volume><fpage>47</fpage><lpage>50</lpage><year>2013</year> <comment>(In Chinese)</comment><pub-id pub-id-type="pmid">23662406</pub-id></element-citation></ref>
<ref id="b30-etm-0-0-6502"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>WP</given-names></name><name><surname>Bai</surname><given-names>XJ</given-names></name><name><surname>Zheng</surname><given-names>XP</given-names></name><name><surname>Xie</surname><given-names>XL</given-names></name><name><surname>Yuan</surname><given-names>ZY</given-names></name></person-group><article-title>Icariin attenuates the enhanced prothrombotic state in atherosclerotic rabbits independently of its lipid-lowering effects</article-title><source>Planta Med</source><volume>79</volume><fpage>731</fpage><lpage>736</lpage><year>2013</year><pub-id pub-id-type="doi">10.1055/s-0032-1328551</pub-id><pub-id pub-id-type="pmid">23700112</pub-id></element-citation></ref>
<ref id="b31-etm-0-0-6502"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xin</surname><given-names>H</given-names></name><name><surname>Zhou</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>GY</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Gao</surname><given-names>ZZ</given-names></name><name><surname>Bai</surname><given-names>GY</given-names></name><name><surname>Lu</surname><given-names>H</given-names></name><name><surname>Xin</surname><given-names>ZC</given-names></name></person-group><article-title>Icariin ameliorates streptozotocin-induced diabetic retinopathy in vitro and in vivo</article-title><source>Int J Mol Sci</source><volume>13</volume><fpage>866</fpage><lpage>878</lpage><year>2012</year><pub-id pub-id-type="doi">10.3390/ijms13010866</pub-id><pub-id pub-id-type="pmid">22312291</pub-id></element-citation></ref>
<ref id="b32-etm-0-0-6502"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qi</surname><given-names>MY</given-names></name><name><surname>Kai</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>HR</given-names></name><name><surname>Su</surname><given-names>YH</given-names></name><name><surname>Yu</surname><given-names>SQ</given-names></name></person-group><article-title>Protective effect of Icariin on the early stage of experimental diabetic nephropathy induced by streptozotocin via modulating transforming growth factor beta1 and type IV collagen expression in rats</article-title><source>J Ethnopharmacol</source><volume>138</volume><fpage>731</fpage><lpage>736</lpage><year>2011</year><pub-id pub-id-type="doi">10.1016/j.jep.2011.10.015</pub-id><pub-id pub-id-type="pmid">22027446</pub-id></element-citation></ref>
<ref id="b33-etm-0-0-6502"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>YF</given-names></name><name><surname>Xu</surname><given-names>YY</given-names></name><name><surname>Jin</surname><given-names>F</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Shi</surname><given-names>JS</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name></person-group><article-title>Icariin is a PPAR&#x03B1; activator inducing lipid metabolic gene expression in mice</article-title><source>Molecules</source><volume>19</volume><fpage>18179</fpage><lpage>18191</lpage><year>2014</year><pub-id pub-id-type="doi">10.3390/molecules191118179</pub-id><pub-id pub-id-type="pmid">25383754</pub-id></element-citation></ref>
<ref id="b34-etm-0-0-6502"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tran</surname><given-names>B</given-names></name><name><surname>Oliver</surname><given-names>S</given-names></name><name><surname>Rosa</surname><given-names>J</given-names></name><name><surname>Galassetti</surname><given-names>P</given-names></name></person-group><article-title>Aspects of inflammation and oxidative stress in pediatric obesity and type 1 diabetes: An overview of ten years of studies</article-title><source>Exp Diabetes Res</source><volume>2012</volume><fpage>683680</fpage><year>2012</year><pub-id pub-id-type="doi">10.1155/2012/683680</pub-id><pub-id pub-id-type="pmid">23093953</pub-id></element-citation></ref>
<ref id="b35-etm-0-0-6502"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Devaraj</surname><given-names>S</given-names></name><name><surname>Dasu</surname><given-names>MR</given-names></name><name><surname>Rockwood</surname><given-names>J</given-names></name><name><surname>Winter</surname><given-names>W</given-names></name><name><surname>Griffen</surname><given-names>SC</given-names></name><name><surname>Jialal</surname><given-names>I</given-names></name></person-group><article-title>Increased toll-like receptor (TLR) 2 and TLR4 expression in monocytes from patients with type 1 diabetes: Further evidence of a proinflammatory state</article-title><source>J Clin Endocrinol Metab</source><volume>93</volume><fpage>578</fpage><lpage>583</lpage><year>2008</year><pub-id pub-id-type="doi">10.1210/jc.2007-2185</pub-id><pub-id pub-id-type="pmid">18029454</pub-id></element-citation></ref>
<ref id="b36-etm-0-0-6502"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Devaraj</surname><given-names>S</given-names></name><name><surname>Glaser</surname><given-names>N</given-names></name><name><surname>Griffen</surname><given-names>S</given-names></name><name><surname>Wang-Polagruto</surname><given-names>J</given-names></name><name><surname>Miguelino</surname><given-names>E</given-names></name><name><surname>Jialal</surname><given-names>I</given-names></name></person-group><article-title>Increased monocytic activity and biomarkers of inflammation in patients with type 1 diabetes</article-title><source>Diabetes</source><volume>55</volume><fpage>774</fpage><lpage>779</lpage><year>2006</year><pub-id pub-id-type="doi">10.2337/diabetes.55.03.06.db05-1417</pub-id><pub-id pub-id-type="pmid">16505242</pub-id></element-citation></ref>
<ref id="b37-etm-0-0-6502"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamagishi</surname><given-names>S</given-names></name></person-group><article-title>Advanced glycation end products and receptor-oxidative stress system in diabetic vascular complications</article-title><source>Ther Apher Dial</source><volume>13</volume><fpage>534</fpage><lpage>539</lpage><year>2009</year><pub-id pub-id-type="doi">10.1111/j.1744-9987.2009.00775.x</pub-id><pub-id pub-id-type="pmid">19954478</pub-id></element-citation></ref>
<ref id="b38-etm-0-0-6502"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maritim</surname><given-names>AC</given-names></name><name><surname>Sanders</surname><given-names>RA</given-names></name><name><surname>Watkins</surname><given-names>JB</given-names><suffix>III</suffix></name></person-group><article-title>Diabetes, oxidative stress and antioxidants: A review</article-title><source>J Biochem Mol Toxicol</source><volume>17</volume><fpage>24</fpage><lpage>38</lpage><year>2003</year><pub-id pub-id-type="doi">10.1002/jbt.10058</pub-id><pub-id pub-id-type="pmid">12616644</pub-id></element-citation></ref>
<ref id="b39-etm-0-0-6502"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>T</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Kalionis</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Yuan</surname><given-names>D</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Cai</surname><given-names>W</given-names></name><name><surname>Fang</surname><given-names>H</given-names></name><name><surname>Xia</surname><given-names>S</given-names></name></person-group><article-title>Icariin intervenes in cardiac inflammaging through upregulation of SIRT6 enzyme activity and inhibition of the NF-Kappa B pathway</article-title><source>Biomed Res Int</source><volume>2015</volume><fpage>895976</fpage><year>2015</year><pub-id pub-id-type="pmid">25688369</pub-id></element-citation></ref>
<ref id="b40-etm-0-0-6502"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Yuan</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Ni</surname><given-names>J</given-names></name><name><surname>Deng</surname><given-names>W</given-names></name><name><surname>Bian</surname><given-names>ZY</given-names></name><name><surname>Dai</surname><given-names>J</given-names></name><name><surname>Tang</surname><given-names>QZ</given-names></name></person-group><article-title>Icariin protects H9c2 cardiomyocytes from lipopolysaccharide-induced injury via inhibition of the reactive oxygen species-dependent c-Jun N-terminal kinases/nuclear factor-kB pathway</article-title><source>Mol Med Rep</source><volume>11</volume><fpage>4327</fpage><lpage>4332</lpage><year>2015</year><pub-id pub-id-type="doi">10.3892/mmr.2015.3289</pub-id><pub-id pub-id-type="pmid">25647547</pub-id></element-citation></ref>
<ref id="b41-etm-0-0-6502"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Lv</surname><given-names>Y</given-names></name><name><surname>Luo</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Dong</surname><given-names>J</given-names></name></person-group><article-title>Regulation of Th17/Treg function contributes to the attenuation of chronic airway inflammation by icariin in ovalbumin-induced murine asthma model</article-title><source>Immunobiology</source><volume>220</volume><fpage>789</fpage><lpage>797</lpage><year>2015</year><pub-id pub-id-type="doi">10.1016/j.imbio.2014.12.015</pub-id><pub-id pub-id-type="pmid">25613226</pub-id></element-citation></ref>
<ref id="b42-etm-0-0-6502"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>R</given-names></name><name><surname>Deng</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Zeng</surname><given-names>G</given-names></name></person-group><article-title>A natural flavonoid glucoside icariin inhibits Th1 and Th17 cell differentiation and ameliorates experimental autoimmune encephalomyelitis</article-title><source>Int Immunopharmacol</source><volume>24</volume><fpage>224</fpage><lpage>231</lpage><year>2015</year><pub-id pub-id-type="doi">10.1016/j.intimp.2014.12.015</pub-id><pub-id pub-id-type="pmid">25528476</pub-id></element-citation></ref>
<ref id="b43-etm-0-0-6502"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chi</surname><given-names>L</given-names></name><name><surname>Gao</surname><given-names>W</given-names></name><name><surname>Shu</surname><given-names>X</given-names></name><name><surname>Lu</surname><given-names>X</given-names></name></person-group><article-title>A natural flavonoid glucoside, icariin, regulates Th17 and alleviates rheumatoid arthritis in a murine model</article-title><source>Mediators Inflamm</source><volume>2014</volume><fpage>392062</fpage><year>2014</year><pub-id pub-id-type="doi">10.1155/2014/392062</pub-id><pub-id pub-id-type="pmid">25374443</pub-id></element-citation></ref>
<ref id="b44-etm-0-0-6502"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Dong</surname><given-names>J</given-names></name></person-group><article-title>Icariin ameliorates cigarette smoke induced inflammatory responses via suppression of NF-kB and modulation of GR in vivo and in vitro</article-title><source>PLoS One</source><volume>9</volume><fpage>e102345</fpage><year>2014</year><pub-id pub-id-type="doi">10.1371/journal.pone.0102345</pub-id><pub-id pub-id-type="pmid">25089961</pub-id></element-citation></ref>
<ref id="b45-etm-0-0-6502"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>M</given-names></name><name><surname>Zhu</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Geng</surname><given-names>D</given-names></name></person-group><article-title>Inhibitory effect of icariin on Ti-induced inflammatory osteoclastogenesis</article-title><source>J Surg Res</source><volume>192</volume><fpage>447</fpage><lpage>453</lpage><year>2014</year><pub-id pub-id-type="doi">10.1016/j.jss.2014.05.038</pub-id><pub-id pub-id-type="pmid">24969548</pub-id></element-citation></ref>
<ref id="b46-etm-0-0-6502"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tao</surname><given-names>F</given-names></name><name><surname>Qian</surname><given-names>C</given-names></name><name><surname>Guo</surname><given-names>W</given-names></name><name><surname>Luo</surname><given-names>Q</given-names></name><name><surname>Xu</surname><given-names>Q</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name></person-group><article-title>Inhibition of Th1/Th17 responses via suppression of STAT1 and STAT3 activation contributes to the amelioration of murine experimental colitis by a natural flavonoid glucoside icariin</article-title><source>Biochem Pharmacol</source><volume>85</volume><fpage>798</fpage><lpage>807</lpage><year>2013</year><pub-id pub-id-type="doi">10.1016/j.bcp.2012.12.002</pub-id><pub-id pub-id-type="pmid">23261528</pub-id></element-citation></ref>
<ref id="b47-etm-0-0-6502"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Fortenbery</surname><given-names>N</given-names></name><name><surname>Eksioglu</surname><given-names>E</given-names></name><name><surname>Kodumudi</surname><given-names>KN</given-names></name><name><surname>Pk</surname><given-names>EB</given-names></name><name><surname>Dong</surname><given-names>J</given-names></name><name><surname>Djeu</surname><given-names>JY</given-names></name><name><surname>Wei</surname><given-names>S</given-names></name></person-group><article-title>Icariin and its derivative, ICT, exert anti-inflammatory, anti-tumor effects and modulate myeloid derived suppressive cells (MDSCs) functions</article-title><source>Int Immunopharmacol</source><volume>11</volume><fpage>890</fpage><lpage>898</lpage><year>2011</year><pub-id pub-id-type="doi">10.1016/j.intimp.2011.01.007</pub-id><pub-id pub-id-type="pmid">21244860</pub-id></element-citation></ref>
<ref id="b48-etm-0-0-6502"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>SR</given-names></name><name><surname>Xu</surname><given-names>XZ</given-names></name><name><surname>Wang</surname><given-names>YH</given-names></name><name><surname>Chen</surname><given-names>JW</given-names></name><name><surname>Xu</surname><given-names>SW</given-names></name><name><surname>Gu</surname><given-names>LQ</given-names></name><name><surname>Liu</surname><given-names>PQ</given-names></name></person-group><article-title>Icariin derivative inhibits inflammation through suppression of p38 mitogen-activated protein kinase and nuclear factor-kappaB pathways</article-title><source>Biol Pharm Bull</source><volume>33</volume><fpage>1307</fpage><lpage>1313</lpage><year>2010</year><pub-id pub-id-type="doi">10.1248/bpb.33.1307</pub-id><pub-id pub-id-type="pmid">20686223</pub-id></element-citation></ref>
<ref id="b49-etm-0-0-6502"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsieh</surname><given-names>TP</given-names></name><name><surname>Sheu</surname><given-names>SY</given-names></name><name><surname>Sun</surname><given-names>JS</given-names></name><name><surname>Chen</surname><given-names>MH</given-names></name></person-group><article-title>Icariin inhibits osteoclast differentiation and bone resorption by suppression of MAPKs/NF-kB regulated HIF-1&#x03B1; and PGE (2) synthesis</article-title><source>Phytomedicine</source><volume>18</volume><fpage>176</fpage><lpage>185</lpage><year>2011</year><pub-id pub-id-type="doi">10.1016/j.phymed.2010.04.003</pub-id><pub-id pub-id-type="pmid">20554188</pub-id></element-citation></ref>
<ref id="b50-etm-0-0-6502"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name></person-group><article-title>Protective effects of icariin on brain dysfunction induced by lipopolysaccharide in rats</article-title><source>Phytomedicine</source><volume>17</volume><fpage>950</fpage><lpage>955</lpage><year>2010</year><pub-id pub-id-type="doi">10.1016/j.phymed.2010.03.007</pub-id><pub-id pub-id-type="pmid">20382007</pub-id></element-citation></ref>
<ref id="b51-etm-0-0-6502"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grey</surname><given-names>ST</given-names></name><name><surname>Longo</surname><given-names>C</given-names></name><name><surname>Shukri</surname><given-names>T</given-names></name><name><surname>Patel</surname><given-names>VI</given-names></name><name><surname>Csizmadia</surname><given-names>E</given-names></name><name><surname>Daniel</surname><given-names>S</given-names></name><name><surname>Arvelo</surname><given-names>MB</given-names></name><name><surname>Tchipashvili</surname><given-names>V</given-names></name><name><surname>Ferran</surname><given-names>C</given-names></name></person-group><article-title>Genetic engineering of a suboptimal islet graft with A20 preserves beta cell mass and function</article-title><source>J Immunol</source><volume>170</volume><fpage>6250</fpage><lpage>6256</lpage><year>2003</year><pub-id pub-id-type="doi">10.4049/jimmunol.170.12.6250</pub-id><pub-id pub-id-type="pmid">12794157</pub-id></element-citation></ref>
<ref id="b52-etm-0-0-6502"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>HB</given-names></name><name><surname>Huang</surname><given-names>ZQ</given-names></name></person-group><article-title>Icariin enhances endothelial nitric-oxide synthase expression on human endothelial cells in vitro</article-title><source>Vascul Pharmacol</source><volume>47</volume><fpage>18</fpage><lpage>24</lpage><year>2007</year><pub-id pub-id-type="doi">10.1016/j.vph.2007.03.002</pub-id><pub-id pub-id-type="pmid">17499557</pub-id></element-citation></ref>
<ref id="b53-etm-0-0-6502"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wo</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>D</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Lou</surname><given-names>Y</given-names></name></person-group><article-title>Involvement of NF-kappaB and AP-1 activation in icariin promoted cardiac differentiation of mouse embryonic stem cells</article-title><source>Eur J Pharmacol</source><volume>586</volume><fpage>59</fpage><lpage>66</lpage><year>2008</year><pub-id pub-id-type="doi">10.1016/j.ejphar.2008.02.080</pub-id><pub-id pub-id-type="pmid">18423597</pub-id></element-citation></ref>
<ref id="b54-etm-0-0-6502"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>KW</given-names></name><name><surname>Fu</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>GX</given-names></name><name><surname>Wang</surname><given-names>XM</given-names></name></person-group><article-title>Icariin attenuates lipopolysaccharide-induced microglial activation and resultant death of neurons by inhibiting TAK1/IKK/NF-kappaB and JNK/p38 MAPK pathways</article-title><source>Int Immunopharmacol</source><volume>10</volume><fpage>668</fpage><lpage>678</lpage><year>2010</year><pub-id pub-id-type="doi">10.1016/j.intimp.2010.03.010</pub-id><pub-id pub-id-type="pmid">20347053</pub-id></element-citation></ref>
<ref id="b55-etm-0-0-6502"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>W</given-names></name><name><surname>Pan</surname><given-names>C</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Gong</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name></person-group><article-title>Heparanase expression in gallbladder carcinoma and its correlation to prognosis</article-title><source>J Gastroenterol Hepatol</source><volume>23</volume><fpage>491</fpage><lpage>497</lpage><year>2008</year><pub-id pub-id-type="doi">10.1111/j.1440-1746.2007.04945.x</pub-id><pub-id pub-id-type="pmid">17524042</pub-id></element-citation></ref>
<ref id="b56-etm-0-0-6502"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>H</given-names></name><name><surname>Guo</surname><given-names>M</given-names></name></person-group><article-title>Synergistic anti-cancer effects of icariin and temozolomide in glioblastoma</article-title><source>Cell Biochem Biophys</source><volume>71</volume><fpage>1379</fpage><lpage>1385</lpage><year>2015</year><pub-id pub-id-type="doi">10.1007/s12013-014-0360-3</pub-id><pub-id pub-id-type="pmid">25384619</pub-id></element-citation></ref>
<ref id="b57-etm-0-0-6502"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>H</given-names></name><name><surname>Xu</surname><given-names>B</given-names></name><name><surname>Hou</surname><given-names>P</given-names></name><name><surname>Jiang</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Tang</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name></person-group><article-title>Icaritin sensitizes human glioblastoma cells to TRAIL-induced apoptosis</article-title><source>Cell Biochem Biophys</source><volume>72</volume><fpage>533</fpage><lpage>542</lpage><year>2015</year><pub-id pub-id-type="doi">10.1007/s12013-014-0499-y</pub-id><pub-id pub-id-type="pmid">25577511</pub-id></element-citation></ref>
<ref id="b58-etm-0-0-6502"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Wei</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>Z</given-names></name><name><surname>Gong</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Hou</surname><given-names>Q</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Chai</surname><given-names>J</given-names></name><name><surname>Zou</surname><given-names>L</given-names></name><name><surname>Zhou</surname><given-names>T</given-names></name></person-group><article-title>Icariin enhances radiosensitivity of colorectal cancer cells by suppressing NF-kB activity</article-title><source>Cell Biochem Biophys</source><volume>69</volume><fpage>303</fpage><lpage>310</lpage><year>2014</year><pub-id pub-id-type="doi">10.1007/s12013-013-9799-x</pub-id><pub-id pub-id-type="pmid">24590261</pub-id></element-citation></ref>
<ref id="b59-etm-0-0-6502"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>DB</given-names></name><name><surname>Li</surname><given-names>XX</given-names></name><name><surname>Zheng</surname><given-names>HT</given-names></name><name><surname>Li</surname><given-names>DW</given-names></name><name><surname>Cai</surname><given-names>GX</given-names></name><name><surname>Peng</surname><given-names>JJ</given-names></name><name><surname>Gu</surname><given-names>WL</given-names></name><name><surname>Guan</surname><given-names>ZQ</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Cai</surname><given-names>SJ</given-names></name></person-group><article-title>Icariin-mediated inhibition of NF-kB activity enhances the in vitro and in vivo antitumour effect of 5-fluorouracil in colorectal cancer</article-title><source>Cell Biochem Biophys</source><volume>69</volume><fpage>523</fpage><lpage>530</lpage><year>2014</year><pub-id pub-id-type="doi">10.1007/s12013-014-9827-5</pub-id><pub-id pub-id-type="pmid">24435883</pub-id></element-citation></ref>
<ref id="b60-etm-0-0-6502"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gazdar</surname><given-names>AF</given-names></name><name><surname>Chick</surname><given-names>WL</given-names></name><name><surname>Oie</surname><given-names>HK</given-names></name><name><surname>Sims</surname><given-names>HL</given-names></name><name><surname>King</surname><given-names>DL</given-names></name><name><surname>Weir</surname><given-names>GC</given-names></name><name><surname>Lauris</surname><given-names>V</given-names></name></person-group><article-title>Continuous, clonal, insulin- and somatostatin-secreting cell lines established from a transplantable rat islet cell tumor</article-title><source>Proc Natl Acad Sci USA</source><volume>77</volume><fpage>3519</fpage><lpage>3523</lpage><year>1980</year><pub-id pub-id-type="doi">10.1073/pnas.77.6.3519</pub-id><pub-id pub-id-type="pmid">6106192</pub-id></element-citation></ref>
<ref id="b61-etm-0-0-6502"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Praz</surname><given-names>GA</given-names></name><name><surname>Halban</surname><given-names>PA</given-names></name><name><surname>Wollheim</surname><given-names>CB</given-names></name><name><surname>Blondel</surname><given-names>B</given-names></name><name><surname>Strauss</surname><given-names>AJ</given-names></name><name><surname>Renold</surname><given-names>AE</given-names></name></person-group><article-title>Regulation of immunoreactive-insulin release from a rat cell line (RINm5F)</article-title><source>Biochem J;</source><volume>210</volume><fpage>345</fpage><lpage>352</lpage><year>1983</year><pub-id pub-id-type="doi">10.1042/bj2100345</pub-id><pub-id pub-id-type="pmid">6134520</pub-id></element-citation></ref>
</ref-list>
</back>
<floats-group>
<fig id="f1-etm-0-0-6502" position="float">
<label>Figure 1.</label>
<caption><p>Icariin prevents cytokine-induced cell death in RINm5F cells. RINm5F cells were treated with icariin at 5 or 10 &#x00B5;M with or without IL-1&#x03B2; and IFN-&#x03B3; stimulation and cell viability was assessed using an MTT assay. &#x002A;P&#x003C;0.05 vs. control and <sup>#</sup>P&#x003C;0.05 vs. IL-1&#x03B2;&#x002B;IFN-&#x03B3;. IL, interleukin; IFN, interferon.</p></caption>
<graphic xlink:href="etm-16-03-2756-g00.tif"/>
</fig>
<fig id="f2-etm-0-0-6502" position="float">
<label>Figure 2.</label>
<caption><p>Icariin prevents cytokine-induced NO production in RINm5F cells. RINm5F cells were treated with 5 or 10 &#x00B5;M icariin with or without IL-1&#x03B2; and IFN-&#x03B3; stimulation. (A) NO production and (B) iNOS levels were detected using a colorimetric assay, reverse transcription-quantitative polymerase chain reaction and western blotting, respectively. &#x002A;P&#x003C;0.05 vs. control and <sup>#</sup>P&#x003C;0.05 vs. IL-1&#x03B2;&#x002B;IFN-&#x03B3;. NO, nitric oxide; IL, interleukin; IFN, interferon; iNOS, inducible nitric oxide synthase.</p></caption>
<graphic xlink:href="etm-16-03-2756-g01.tif"/>
</fig>
<fig id="f3-etm-0-0-6502" position="float">
<label>Figure 3.</label>
<caption><p>Icariin inhibits cytokine-induced caspase-3 activation and PARP cleavage as well as cell apoptosis in RINm5F cells. RINm5F cells were treated with icariin at 5 or 10 &#x00B5;M with or without IL-1&#x03B2; and IFN-&#x03B3; stimulation. Subsequently, caspase-3 activation and PARP cleavage were determined using (A) ELISA and (B) western blotting assays. (C) Cell apoptosis was detected using flow cytometry with Annexin V-Allophycocyanin and propidium iodide staining. &#x002A;P&#x003C;0.05 vs. control, <sup>#</sup>P&#x003C;0.05 vs. IL-1&#x03B2;&#x002B;IFN-&#x03B3;. PARP, poly ADP-ribose polymerase; IL, interleukin; IFN, interferon.</p></caption>
<graphic xlink:href="etm-16-03-2756-g02.tif"/>
</fig>
<fig id="f4-etm-0-0-6502" position="float">
<label>Figure 4.</label>
<caption><p>Icariin inhibits cytokine-induced NF-&#x03BA;B activation in RINm5F cells. RINm5F cells were treated with icariin at 5 or 10 &#x00B5;M with or without IL-1&#x03B2; and IFN-&#x03B3; stimulation. (A) NF-&#x03BA;B activation and (B) p65 nucleic localization were further analyzed using ELISA and western blotting, respectively. &#x002A;P&#x003C;0.05 vs. control, <sup>#</sup>P&#x003C;0.05 vs. IL-1&#x03B2;&#x002B;IFN-&#x03B3;. NF, nuclear factor; IL, interleukin; IFN, interferon.</p></caption>
<graphic xlink:href="etm-16-03-2756-g03.tif"/>
</fig>
</floats-group>
</article>
